Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient

Journal of Dermatology

Volumn 44, Issue 5, 2017, Pages 605-606

  Teramoto, Yukiko ^a   Nakamura, Yasuhiro ^a   Asami, Yuri ^a   Imamura, Taichi ^a   Takahira, Shuji ^a   Nemoto, Manabu ^a   Sakai, Gota ^b   Shimada, Akira ^b   Noda, Mitsuhiko ^b   Yamamoto, Akifumi ^a  

^a SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; BICARBONATE; C PEPTIDE; DACARBAZINE; ELASTASE; ELASTASE I; GLUCOSE; HEMOGLOBIN A1C; INSULIN; KETONE BODY; NIVOLUMAB; UNCLASSIFIED DRUG; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ADULT; AMYLASE BLOOD LEVEL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CASE REPORT; DIABETIC KETOACIDOSIS; DISEASE ASSOCIATION; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN TREATMENT; LETTER; MELANOMA; MIDDLE AGED; PH; POLYDIPSIA; POLYURIA; VULVAR MELANOMA; CHEMICALLY INDUCED; DISEASE EXACERBATION; VULVA TUMOR;

ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; FEMALE; HUMANS; MELANOMA; MIDDLE AGED; NIVOLUMAB; VULVAR NEOPLASMS;

EID: 85018663057     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.13486     Document Type: Letter

References (4)

1. Imagawa A, Hanafusa T, Awata T et al. Report of the committee of the Japan diabetes society on the research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus (2012). J Diabetes Investig 2012; 3: 536–539.
2. Gaudy C, Clevy C, Monestier S et al. Anti-PD1 pembrolizumab can induce exceptional fulminant type 1 diabetes. Diabetes Care 2015; 38: e182–e183.
3. Hughes J, Vudattu N, Sznol M et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care 2015; 38: e55–e57.
4. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320–330.